Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Conditions

• Bacterial Conjunctivitis

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Fusidic Acid 1% — DRUG
  Fusidic acid 1%
• Placebo — DRUG
  Placebo ophthalmic solution

Study Details

The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.

Key Dates

Start date

Mar 21, 2025

Status verified

Dec 2025

Primary completion

Mar 16, 2026

Completion

Mar 23, 2026

Study Design

Enrollment

400 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Fusidic Acid 1%
  Participants will instill one drop of fusidic acid 1% per eye twice a day (BID) for 7 days. Approximately 12 hours between doses is preferred, but BID administration takes precedence over precise timing
• Placebo Comparator: Placebo
  Participants will instill one drop of Placebo ophthalmic solution per eye BID for 7 days. Approximately 12 hours between doses is preferred, but BID administration takes precedence over precise timing

Primary Outcome Measure

Clinical Cure [ Time Frame: Visit 2 (Day 4) ]

Central Contacts

• Director of Clinical Operations
  4349808100
  [email protected]

Locations (38)

Find similar trials in Little Rock, AR

Related Studies

• Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
  PHASE1/PHASE2 · Not Yet Recruiting · Senju USA, Inc. · Austin, Texas